Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Regents of the University of California has licensed a new series of antifibrinolytic agents to Omeros, a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.
Subscribe to our email newsletter
Omeros claims that its proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding inhibition of Factor XIa and kallikrein.
Omeros chairman and CEO Gregory Demopulos said that this is a good opportunity for Omeros and represents a potential life-saving treatment for patients.
"The ex vivo human and in-vivo animal efficacy data look strong, and the regulatory pathway is well-defined," Demopulos said.
"We have begun IND-enabling activities and are working to advance the program quickly to the clinic."